SCHEMBL2411253

SCHEMBL2411253

Cc1ccc(CCC(=O)c2c(O)c3cccnc3n(-c3ccccc3)c2=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.45
FEN1 P39748 1/20 0.44
PDE1A P54750 1/20 0.43
PDE1B Q01064 1/20 0.43
PDE4A P27815 6/20 0.43
PDE4B Q07343 5/20 0.43
PDE4C Q08493 5/20 0.43
PDE4D Q08499 5/20 0.43
MAPT P10636 2/20 0.43
RECQL P46063 1/20 0.42
MAPK8 P45983 1/20 0.41
SLC5A1 P13866 1/20 0.41
SLC5A2 P31639 1/20 0.41
THRB P10828 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2413828 0.93 PDE1A (0.49) FEN1PDE1APDE1BPDE4APDE4B
SCHEMBL2411173 0.90 FEN1 (0.46) FEN1PDE1APDE1BPDE4APDE4B
SCHEMBL2412337 0.87 USP14 (0.45) FEN1PDE1APDE1BPDE4APDE4B
SCHEMBL2411216 0.87 PDE1A (0.46) FEN1PDE1APDE1BPDE4APDE4B
SCHEMBL2408445 0.86 PDE1A (0.47) FEN1PDE1APDE1BPDE4APDE4B
SCHEMBL2412845 0.86 MAPT (0.45) FEN1PDE1APDE1BPDE4APDE4B
SCHEMBL4187018 0.84 ACHE (0.47) FEN1PDE1APDE1BPDE4A
SCHEMBL2412660 0.82 PDE1A (0.42) FEN1PDE1APDE1BPDE4APDE4B
SCHEMBL2409456 0.82 PDE1A (0.51) FEN1PDE1APDE1BPDE4APDE4B
SCHEMBL2414794 0.81 PTGDR2 (0.46) FEN1PDE1APDE1BPDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559716-B1 PYRAZOLONAPHTHYRIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-09-14 EP disclosed
US-20100093782-A1 Pyrazolonaphthyridine derivatives KANAZAWA HASHIME 2010-04-15 US disclosed
US-7608716-B2 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-10-27 US disclosed
US-20060040972-A1 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-23 US disclosed
EP-1559716-A1 PYRAZOLONAPHTHYRIDINE DERIVATIVE Grelan Pharmaceutical Co., Ltd. (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040972-A1 Pyrazolonaphthyridine derivative PDE3B, PDE3A, PDE4A RXFP1 161/4885FEN1 1590/4885PDE1A 28/4885
US-20100093782-A1 Pyrazolonaphthyridine derivatives PDE3B, PDE3A, PDE4A RXFP1 183/4885FEN1 1789/4885PDE1A 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.